Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 3, 2010, Pages 270-278

  Blanco, Isabel ^a   Gimeno, Elena ^a   Munoz, Phillip A ^b   Pizarro, Sandra ^a   Gistau, Concepción ^a   Rodriguez Roisin, Robert ^a,b   Roca, Josep ^a,b   Barberá, Joan Albert ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Arterial oxygen pressure; Phosphodiesterase 5 inhibitors; Pulmonary circulation; Vasodilator agents; Ventilation perfusion relationships

Indexed keywords

SILDENAFIL;

ADULT; AGED; ARTERIAL OXYGEN SATURATION; ARTICLE; BLOOD GAS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; EXERCISE; FEMALE; GAS EXCHANGE; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VENTILATION PERFUSION RATIO; MALE; MEAN ARTERIAL PRESSURE; OXYGEN TENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REST; SINGLE DRUG DOSE; SPIROMETRY;

3',5'-CYCLIC-GMP PHOSPHODIESTERASES; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PIPERAZINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY GAS EXCHANGE; PULMONARY WEDGE PRESSURE; PURINES; REST; SEVERITY OF ILLNESS INDEX; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 76749160426     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200907-0988OC     Document Type: Article

References (46)

1. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, Mal H. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127:1531-1536.
2. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 1995;107:1193-1198.
3. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:158-164.
4. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, Ehrhart M, Oswald-Mammosser M. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164:219-224.
5. Barberà JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003;21:892-905.
6. Zielinski J, Tobiasz M, Hawrylkiewicz I, Sliwinski P, Palasiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 1998;113:65-70.
7. Agusti AG, Barberà JA, Roca J, Wagner PD, Guitart R, Rodriguez-Roisin R. Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest 1990; 97:268-275.
8. Barberà JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996;347: 436-440.
9. Katayama Y, HigenbottamTW, Diaz de Atauri MJ, Cremona G, Akamine S, Barberà JA, Rodriguez-Roisin R. Inhaled nitric oxide and arterial oxygen tension in patients with chronic obstructive pulmonary disease and severe pulmonary hypertension. Thorax 1997;52:120-124.
10. Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Butt AY, Large SR, Wells FC, Wallwork J. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991;324:1539-1547.
11. Peinado VI, Barberà JA, Ramirez J, Gomez FP, Roca J, Jover L, Gimferrer JM, Rodriguez-Roisin R. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 1998;274:L908-L913.
12. Peinado VI, Pizarro S, Barberà JA. Pulmonary vascular involvement in COPD. Chest 2008;134:808-814.
13. Ghofrani HA, Pepke-Zaba J, Barberà JA, Channick R, Keogh AM, Gomez-Sanchez MA, Kneussl M, Grimminger F. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:68S-72S.
14. Barberà JA, Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez-Roisin R. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med 2001; 164:709-713.
15. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barberà JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al.; Task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-2537.
16. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
17. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353: 2148-2157.
18. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-530.
19. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, MirrakhimovMM, Aldashev A, WilkinsMR. Sildenafil inhibits hypoxiainduced pulmonary hypertension. Circulation 2001;104:424-428.
20. Hoeper MM, Barberà JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009;54: S85-S96.
21. Blanco I, Gimeno E, Munoz PA, Gómez FP, Pizarro S, Gistau C, Rodriguez-Roisin R, Roca J, Barberà JA. Acute effects of sildenafil in chronic obstructive pulmonary disease (COPD) [abstract]. Eur Respir J 2008;32:167S.
22. Blanco I, Gimeno E, Munoz PA, Gómez FP, Pizarro S, Gistau C, Rodriguez-Roisin R, Roca J, Barberà JA. Sildenafil in pulmonary hypertension associated with COPD [abstract]. Am J Respir Crit Care Med 2009;179:A1046.
23. Peces-Barba G, Barberà JA, Agusti A, Casanova C, Casas A, Izquierdo JL, Jardim J, Lopez V, Monso E, Montemayor T, Viejo JL. Diagnosis and management of chronic obstructive pulmonary disease: joint guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT). Arch Bronconeumol 2008;44:271-281.
24. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
25. Roger N, Barberà JA, Roca J, Rovira I, Gomez FP, Rodriguez-Roisin R. Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:800-806.
26. Wagner PD. The multiple inert gas elimination technique (MIGET). Intensive Care Med 2008;34:994-1001.
27. Cardus J, Burgos F, Diaz O, Roca J, Barberà JA, Marrades RM, Rodriguez-Roisin R, Wagner PD. Increase in pulmonary ventilation-perfusion inequality with age in healthy individuals. Am J Respir Crit Care Med 1997;156:648-653.
28. Roca J, Wagner PD. Contribution of multiple inert gas elimination technique to pulmonary medicine. 1. Principles and information content of the multiple inert gas elimination technique. Thorax 1994;49:815-824.
29. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900.
30. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371-1385.
31. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009;34:888-894.
32. Rodriguez-Roisin R, Drakulovic M, Rodriguez DA, Roca J, Barbera JA, Wagner PD. Ventilation-perfusion imbalance and chronic obstructive pulmonary disease staging severity. J Appl Physiol 2009;106: 1902-1908.
33. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
34. Morrell NW, Higham MA, Phillips PG, Shakur BH, Robinson PJ, Beddoes RJ. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respir Res 2005;6:88.
35. Stolz D, Rasch H, Linka A, Valentino MD, Meyer A, Brutsche M, Tamm M. A randomized, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-628.
36. Hoeper MM. Treating pulmonary hypertension in COPD: where do we start? Eur Respir J 2008;32:541-542.
37. Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin LJ, Olschewski H, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008;21:824-832.
38. Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, Christie JD. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 2009;136:412-419.
39. Barberà JA, Riverola A, Roca J, Ramirez J, Wagner PD, Ros D, Wiggs BR, Rodriguez-Roisin R. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;149:423-429.
40. Melot C, Hallemans R, Naeije R, Mols P, Lejeune P. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984;130:612-616.
41. Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez-Roisin R, Barberà JA. Response to hypoxia of pulmonary arteries in chronic obstructive pulmonary disease: an in vitro study. Eur Respir J 2002;20:332-338.
42. Charan NB. Does sildenafil also improve breathing? Chest 2001;120:305-306.
43. Hammond MD, Gale GE, Kapitan KS, Ries A, Wagner PD. Pulmonary gas exchange in humans during normobaric hypoxic exercise. J Appl Physiol 1986;61:1749-1757.
44. Puente-Maestu L, Sanz ML, Sanz P, Nunez A, Gonzalez F, Whipp BJ. Reproducibility of the parameters of the on-transient cardiopulmonary responses during moderate exercise in patients with chronic obstructive pulmonary disease. Eur J Appl Physiol 2001;85:434-441.
45. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55-S66.
46. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981;36:752-758.